MAZE THERAPEUTICS, INC. Operating Expenses
MAZE THERAPEUTICS, INC. (MAZE) reported Operating Expenses of $48.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $48.03M, a 31.70% increase year-over-year.
- MAZE THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $46.55M, a 31.50% increase year-over-year.
- MAZE THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $38.06M, a 28.03% increase year-over-year.
- MAZE THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $32.97M, a 23.33% increase year-over-year.
- MAZE THERAPEUTICS, INC. operating expenses for fiscal 2025 was $142.90M, a 30.01% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. operating expenses for fiscal 2024 was $109.91M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.03M 10-Q · filed 2026-08-11 | $94.59M 10-Q · filed 2026-08-11 | $132.65M derived: sum of 3 quarters · filed 2026-08-11 | $165.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $46.55M 10-Q · filed 2026-05-12 | $84.61M derived: sum of 2 quarters · filed 2026-05-12 | $117.58M derived: sum of 3 quarters · filed 2026-05-12 | $154.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $38.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $71.02M derived: sum of 2 quarters · filed 2026-03-25 | $107.50M derived: sum of 3 quarters · filed 2026-08-11 | $142.90M 10-K · filed 2026-03-25 |
| 2025-09-30 | $32.97M 10-Q · filed 2025-11-06 | $69.44M derived: sum of 2 quarters · filed 2026-08-11 | $104.84M 10-Q · filed 2025-11-06 | $134.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $36.47M 10-Q · filed 2026-08-11 | $71.88M 10-Q · filed 2026-08-11 | $101.60M derived: sum of 3 quarters · filed 2026-08-11 | $128.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $35.40M 10-Q · filed 2026-05-12 | $65.13M derived: sum of 2 quarters · filed 2026-05-12 | $91.86M derived: sum of 3 quarters · filed 2026-05-12 | $117.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $29.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $56.45M derived: sum of 2 quarters · filed 2026-03-25 | $81.90M derived: sum of 3 quarters · filed 2026-03-25 | $109.91M 10-K · filed 2026-03-25 |
| 2024-09-30 | $26.73M 10-Q · filed 2025-11-06 | $52.17M derived: sum of 2 quarters · filed 2025-11-06 | $80.19M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $25.45M 10-Q · filed 2025-08-12 | $53.46M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $28.01M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |